ALNY vs IONS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ALNY is the larger of the two ($20.06B market cap): the incumbent the market prices for continued execution (15.12x forward earnings, beta 0.44). IONS is the smaller challenger ($4.58B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, IONS fits: analysts expect its revenue to rise 25% next year, against 17% for ALNY. If you believe in profit, ALNY fits: it is expected to make money next year (15.12x forward earnings), while IONS is still expected to post a loss.
ALNY vs IONS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALNY | IONS | What it tells you |
|---|---|---|---|
| Market cap | $20.06B | $4.58B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.12 | -13.58 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.44 | 0.40 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 1% of range | 2% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.56 | 11.63 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ALNY and IONS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALNY and IONS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALNY and IONS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alnylam Pharmaceuticals (ALNY) do?
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Its commercial portfolio includes Amvuttra (vutrisiran) and Onpattro for transthyretin (TTR) amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for a rare kidney disorder, plus royalties on Leqvio, a cholesterol-lowering RNAi drug marketed by partner Novartis. On November 19, 2026 collaborator Regeneron won FDA approval for Livsayis (cemdisiran) in generalized myasthenia gravis, which Alnylam counts as the seventh FDA-approved therapeutic from its RNAi platform in under nine years. The defining event was the March 2025 FDA approval of Amvuttra for ATTR amyloidosis with cardiomyopathy (ATTR-CM), a far larger patient population than its earlier polyneuropathy indication, based on the HELIOS-B trial showing a 28% reduction in death and cardiac events.
What does Ionis Pharmaceuticals (IONS) do?
Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. For decades it operated largely as an R&D and royalty engine, partnering drugs like Spinraza (spinal muscular atrophy, with Biogen) and Wainua (hereditary ATTR polyneuropathy, with AstraZeneca) to larger companies. It now has seven approved medicines covering eight indications and, starting in 2025, launched its first fully owned products, Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema.
ALNY vs IONS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ALNY drivers: Amvuttra ATTR-CM ramp; Profitability and capital return.
- IONS drivers: Owned commercial launches; Olezarsen in severe hypertriglyceridemia.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue is heavily concentrated in the TTR franchise, and 2026 showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the revenue range in July produced a 28% one-day drop, and guiding to the low end in October produced another 25% drop. For IONS, ionis still operates at a loss, with a trailing-twelve-month net loss of about $547 million and operating cash outflow of about $544 million, so profitability remains unproven.
ALNY or IONS: which should you pick?
If the story you believe is ALNY's (Amvuttra ATTR-CM ramp), ALNY is the more direct way to own it; if it is IONS's (Owned commercial launches), IONS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALNY and IONS guides.
ALNY vs IONS: the full fundamentals
ALNY. After a 63% decline in 2026, Alnylam trades at about 4 times trailing revenue and about 15 times forward earnings; the trailing P/E near 7.6 is flattered by the one-time tax benefit and is not a fair read of the run rate. Consensus still expects about $5.4 billion of total revenue in 2026 and about $6.4 billion in 2027, so the valuation now hinges on whether first-line Amvuttra demand reaccelerates and what 2027 guidance shows in February. Twenty-seven analysts carry a mean target near $285, far above the price.
IONS. Ionis trades as a growth-stage biotech, valued on future product sales and not current earnings since it remains unprofitable. After a ~66% fall in 2026 the stock sits near 4.8 times trailing sales, down from about 8 times in mid-October, as two Phase 3 setbacks and a slow early sHTG launch reset expectations even though quarterly losses keep coming in narrower than forecast. The 23 analysts tracked have a mean target near $67.83, well above the price, and the market value of ~$4.6 billion is now not far above the company's ~$1.9 billion of cash.
Headline figures (approximate, November 2026): ALNY shows total revenue (ttm) ~$5.0B, total revenue growth (q3 2026 yoy) ~17% (to ~$1.46B), ttr franchise sales (q3 2026) ~$1.15B, up ~59%, 2026 ttr guidance low end of ~$4.2B to $4.5B (cut in July from $4.4B to $4.7B); IONS shows market cap ~$4.6B (share price ~$27.52 on Nov 20, 2026), revenue (ttm) ~$960M (+~55% YoY latest quarter); 2025 revenue ~$944M, q3 2026 revenue ~$243M (Q2 2026 ~$268M); EPS -$0.40 vs -$0.93 estimate, revenue consensus ~$923M for 2026; ~$1.15B for 2027.
The bottom line: ALNY vs IONS
ALNY and IONS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ALNY and IONS exposure against your real portfolio. It is not an investment adviser.
Wondering how ALNY or IONS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alnylam Pharmaceuticals
Ask Walnut's AI anything about ALNY and see how it fits what you own.
FAQ
What is the difference between ALNY and IONS?
+
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALNY or IONS the better stock?
+
Neither is universally better. ALNY is the larger incumbent; IONS is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALNY or IONS?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALNY and IONS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALNY vs IONS?
+
ALNY: Revenue is heavily concentrated in the TTR franchise, and 2026 showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the revenue range in July produced a 28% one-day drop, and guiding to the low end in October produced another 25% drop. The ATTR-CM market is a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing, and new RNAi entrants keep raising capital. Part of Q3 sequential growth came from wholesaler inventory, which can reverse. Reported earnings are distorted by the one-time tax benefit, so the trailing P/E near 7.6 overstates how cheap the stock is; on forward estimates it trades near 15 times, and consensus 2027 EPS of about $9.91 is down sharply from 2026's tax-inflated figure. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. Drug pricing pressure, including government price negotiation under the Inflation Reduction Act, and patent or regulatory changes are ongoing overhangs. Debt of about $3.0 billion sits below the cash balance, but the buyback will narrow that cushion. IONS: Ionis still operates at a loss, with a trailing-twelve-month net loss of about $547 million and operating cash outflow of about $544 million, so profitability remains unproven. The share price has fallen about 66% in 2026 and 36% in the month to November 20, 2026, showing how sharply sentiment can turn on clinical and launch news. Two Phase 3 programs, eplontersen in cardiomyopathy and pelacarsen in Lp(a), disappointed in 2026, which removes part of the pipeline value investors had assigned. The Tryngolza sHTG launch is off to a slower start than expected, and the company's $3 billion-plus peak sales goal depends on repeat prescribing broadening; Arrowhead expects a competing drug, REDEMPLO, to be approved in sHTG in Q2 2027. The Tryngolza sHTG label carries warnings for hypersensitivity reactions and liver enzyme abnormalities, which could shape uptake. It competes directly with Alnylam's RNA-interference platform in overlapping rare and cardiovascular diseases, and some of its biggest products are shared with partners like Biogen and AstraZeneca who control much of the commercial reach. Debt of about $2.2 billion now exceeds cash of about $1.9 billion. Pricing pressure, safety findings, and patent or competitive erosion on older drugs add further uncertainty. As a biotech, the shares can be highly volatile around clinical and regulatory events.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALNY or IONS; figures are approximate and dated (as of November 2026). Verify current data before investing.